Quantcast
Last updated on April 16, 2014 at 5:23 EDT

Latest Destination Therapy Stories

2014-03-18 08:31:41

SynCardia Systems, Inc. Continues to Make Progress for Approval of the SynCardia Heart for Permanent Use to Save Patients Who Are Unlikely to Receive Another Donor Heart TUCSON, Ariz., March 18, 2014 /PRNewswire/ -- SynCardia Systems, Inc. is moving forward to gain FDA approval to use the SynCardia temporary Total Artificial Heart as destination therapy (a permanent replacement heart), which could save patients whose donor heart transplant is failing and are unlikely to receive another...

2014-03-11 16:26:25

Once Results of Studies Are Approved by the FDA, the Smaller 50cc SynCardia Heart and New Permanent Use Indication Will Triple the Number of Heart Failure Patients Who Can Get a 2nd Chance at Life TUCSON, Ariz., March 11, 2014 /PRNewswire/ -- Recent developments surrounding the SynCardia temporary Total Artificial Heart will make the life-saving device available to three times the number of people suffering from end-stage biventricular heart failure. Over 300 SynCardia Hearts have...

2014-03-07 08:26:22

FRAMINGHAM, Mass., March 7, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2014 Barclays Global Healthcare Conference at 10:15 a.m. EDT on Tuesday, March 11, 2014. The conference is being held March 11-13 at Loews Miami Hotel. A live webcast of...

2014-03-04 08:33:06

AHA-Tucson Division Names SynCardia Co-Founder Copeland a Heart Hero for His Pioneering Work With Heart Transplants & the SynCardia Total Artificial Heart TUCSON, Ariz., March 4, 2014 /PRNewswire/ -- Internationally renowned heart transplant pioneer Dr. Jack G. Copeland was honored recently as a "Heart Hero" by the American Heart Association in Tucson, Arizona, for his trailblazing work saving lives with heart transplantation, the SynCardia temporary Total Artificial Heart and the use of...

2014-02-26 16:28:47

FRAMINGHAM, Mass., Feb. 26, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 35(th) Annual Institutional Investors Conference at 4:35 p.m. EST on Tuesday, March 4, 2014. The conference is being held March 2-5 at JW Marriott Grande...

2014-02-04 16:28:02

FRAMINGHAM, Mass., Feb. 4, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2014 Leerink Global Healthcare Conference at 8:55 a.m. EST on Thursday, February 13, 2014. The conference is being held February 12-13 at the Waldorf Astoria in New York...

2013-12-20 08:26:11

FRAMINGHAM, Mass., Dec. 20, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 32(nd) Annual J.P. Morgan Healthcare Conference at 1:30 p.m. Pacific Standard Time (4:30 p.m. EST) on Tuesday, January 14, 2014. The conference is being held January 13-16 at...

2013-12-09 08:30:59

PLEASANTON, Calif., Dec. 9, 2013 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that its Board of Directors has authorized the repurchase of up to $200 million of the company's shares of common stock effective through the end of 2015. The company's previous share repurchase authorization will expire at the end of 2013. "This authorization...

2013-12-06 08:24:46

FRAMINGHAM, Mass., Dec. 6, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference at 7:45 a.m. ET on Wednesday, December 11, 2013. The conference is being held December 10-11, 2013 at The Crowne Plaza Hotel in...

2013-12-01 20:21:19

- Acquisition expands HeartWare's technology platform into partial support for less sick patients - FRAMINGHAM, Mass. and TEANECK, N.J., Dec. 1, 2013 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has acquired CircuLite(®), Inc. - developer of the SYNERGY(®) Circulatory Support System, designed to treat...